For the Quarter Ending September 2024
North America
During Q3 2024, the pricing landscape for Amlodipine Besylate in North America exhibited remarkable stability, marked by consistent market conditions throughout the quarter. Several key factors contributed to this stability, including steady demand from end-users and stable supply levels, resulting in a well-balanced equilibrium between supply and demand dynamics.
In the USA, where the most significant price fluctuations occurred, market trends reflected the broader North American environment. While the quarter recorded a slight percentage decrease in prices compared to the previous quarter, this adjustment was minor and did not indicate any drastic changes. Furthermore, a comparison between the first and second halves of the quarter revealed no substantial price variance, underscoring a period characterized by relative price stability.
As Q3 2024 drew to a close, Amlodipine Besylate was priced at USD 72,985 per metric ton (USP, FDA) CFR Los Angeles. This final price underscored the market's neutral position, reflecting a period where prices remained relatively stable throughout the quarter. Such consistency reinforces the overall trend of stability in the pricing environment for this pharmaceutical product, indicating a balanced interplay of supply and demand without significant fluctuations.
Asia Pacific
In Q3 2024, the APAC region witnessed a pronounced upward trend in Amlodipine Besylate prices, influenced by several key factors. Strong global demand, particularly from major markets, led to heightened precautionary orders, driving prices higher. Compounding this were supply chain disruptions, notably exacerbated by extreme weather events, which constrained supply levels and further fueled price increases. Despite facing challenges such as geopolitical uncertainties and the impact of tariffs, the market maintained a positive sentiment, buoyed by robust demand and favorable supply dynamics. China, in particular, experienced the most significant price fluctuations, mirroring broader trends across the region. The quarter highlighted a consistent upward movement in prices, with a notable 1% increase from the first half to the second half of the quarter. By the end of Q3 2024, Amlodipine Besylate was priced at USD 70,900 per metric ton in China, emphasizing the steady growth trajectory. Market participants actively focused on inventory management strategies to navigate these evolving market conditions. Overall, the quarter showcased a resilient market for Amlodipine Besylate in the APAC region, characterized by strong demand and effective supply management amidst various challenges.
Europe
In Q3 2024, the pricing trend for Amlodipine Besylate in Europe displayed a marked increase, particularly in Germany, where the most significant price changes occurred. Several critical factors contributed to this upward movement in market prices. Firstly, sustained high demand from end-users, along with improving economic conditions and declining inflation rates, created a solid foundation for price growth. Additionally, disruptions in shipping routes, especially due to the ongoing Red Sea crisis, prompted retailers to expedite their inventory replenishment, further fueling price increases. This environment fostered a positive market sentiment, with buyers increasing their purchasing activities to secure adequate inventory levels. While there was a slight decline in prices compared to the previous quarter, the overall trend for the quarter showed a 1% increase in prices from the first half to the second half. By the end of Q3 2024, Amlodipine Besylate was priced at USD 72,725 per metric ton (USP, FDA) CFR Hamburg in Germany, underscoring the upward trajectory in pricing during this period. Overall, the quarter illustrated a robust market for Amlodipine Besylate in Europe, driven by strong demand and proactive inventory management amidst various challenges.
For the Quarter Ending June 2024
North America
In Q2 2024, the North American market for Amlodipine besylate exhibited a mixed trajectory due to a complex interplay of factors shaping the pharmaceutical landscape. The USA experienced the most significant price fluctuations, with an unstable pricing environment throughout the quarter. Prices increased in April and May but decreased in June, influenced by demand dynamics, inventory levels, and global trade activity.
Initially, prices rose due to escalating domestic demand. Consumers, undeterred by cost fatigue, showed a willingness to spend, as evidenced by stronger retail sales, which boosted demand for Amlodipine besylate. Additionally, shipping challenges in the Red Sea region necessitated longer voyages and increased sailing speeds to counter delays. These adjustments led to higher fuel costs and elevated charter rates, while operational bottlenecks further strained shipping capacity, contributing to the price hikes.
However, by the end of the quarter, prices declined due to a downturn in business sentiment, creating economic uncertainty. This lack of confidence affected the pharmaceutical and healthcare industries, resulting in subdued demand for Amlodipine besylate. The quarter concluded with Amlodipine besylate prices at USD 72,100 per metric ton CFR Los Angeles, reflecting a persistently negative pricing environment.
Asia Pacific
In Q2 2024, the pricing landscape for Amlodipine besylate in the APAC region demonstrated a mixed trajectory influenced by various factors. Initially, prices rose due to increased market confidence compared to the previous month. The manufacturing sector continued to expand, driven by a surge in both domestic and international demand, which facilitated a swift acceleration in output growth. Manufacturers responded to this heightened demand by ramping up production levels to capitalize on the influx of new orders. However, prices declined toward the end of the quarter due to an oversupply situation. Increased manufacturing capacities outpaced existing demand, leading to a surplus. Additionally, lower production costs, driven by declining raw material prices and reduced transportation expenses, allowed manufacturers to adjust their pricing strategies downward. External demand remained sluggish as key export markets faced high interest rates, impacting consumer spending on pharmaceutical products. Concluding the quarter, the price of Amlodipine Besylate (USP, FDA) FOB Shanghai stood at USD 70,000 per metric ton, reflecting a stable pricing environment amidst the fluctuating market conditions.
Europe
In Q2 2024, the pricing landscape for Amlodipine besylate in Europe demonstrated a mixed trajectory influenced by several factors. Initially, prices rose as consumer spending increased, leading to higher demand for Amlodipine besylate. This optimistic economic climate was accompanied by elevated supply chain costs, driven by rising wages and high energy prices, which pushed up the cost of goods. However, by June, prices began to decline due to sluggish consumer demand, an overstocked market, and falling freight rates. The economic downturn, combined with reduced illness occurrences associated with warmer weather, further diminished demand. The central bank's decision to maintain unchanged interest rates also added financial pressure on consumers, suppressing purchasing activity. Despite occasional disruptions in the global supply chain, such as port congestion in Asia and North Europe and adverse weather conditions, there was some relief from easing geopolitical tensions and seasonal spikes in cargo volumes. These factors collectively helped to reduce transportation costs, contributing to the further decline in prices. The quarter ended with Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany priced at USD 71,780 per metric ton, reflecting a consistent downward trend throughout the quarter.
For the Quarter Ending March 2024
North America
During Q1 2024, the pricing dynamics of Amlodipine Besylate in the North America region, particularly in the USA, were influenced by a blend of factors. At the outset of the quarter, prices experienced a modest decrease, driven by weakened demand from downstream industries and ample supply in the market. This decline in demand was further exacerbated by the effects of inflation and the Federal Reserve's decision to maintain steady rates.
However, prices surged in the middle of the quarter due to an increase in demand from downstream industries, further straining the already tight supply conditions prevalent in the domestic market. Another significant factor contributing to this heightened demand was the imminent arrival of the spring festival in China, prompting market retailers and distributors to proactively seek replenishment of their inventories. Additionally, disruptions in key maritime routes, such as the Red Sea and Panama Canal, posed challenges for shippers importing Amlodipine Besylate into the US, further exacerbating supply constraints. Nevertheless, prices experienced a significant decline again in March due to a downturn in business sentiments, which has cast a shadow of uncertainty over the economy. This lack of confidence has translated into subdued demand from end-user pharmaceutical and healthcare industries, leading to a downward trajectory in Amlodipine Besylate prices.
Looking at the year-over-year comparison, the price of Amlodipine Besylate in Q1 2024 was lower than the same quarter last year, reflecting the overall decrease in pricing. The final price for Amlodipine Besylate (USP, FDA) CFR Los Angeles in the USA at the end of the quarter was USD 73500/MT.
Asia Pacific
In Q1 2024, the pricing dynamics of Amlodipine Besylate in the APAC region, particularly in China, displayed a nuanced pattern influenced by various factors. These factors encompassed domestic manufacturing activity, global economic conditions, and disruptions in the supply chain. At the beginning of the quarter, prices experienced a slight decline as diminished demand from downstream sectors had a negative impact on the market. The manufacturing environment in China faced challenges, characterized by a slow domestic recovery and subdued external demand. Midway through the quarter, prices surged due to constrained inventories serving as a primary catalyst. The Spring Festival resulted in the closure or reduced operation of numerous factories, disrupting production and causing a shortage in the market. This supply-demand imbalance naturally led to an increase in prices as buyers competed for the limited available stock. However, prices declined again in March despite an uptick in economic activity in China following an extended holiday period. This positive momentum was overshadowed by concerns surrounding inadequate domestic demand. In terms of year-over-year comparison, the pricing of Amlodipine Besylate in Q1 2024 remained relatively stable compared to the same quarter last year. However, there was a decline in pricing compared to the last quarter of 2023, reflecting the overall downward trend. The final quarter's price for Amlodipine Besylate (USP, FDA) FOB Shanghai in China was assessed at USD 70000/MT, indicating a stable pricing level.
Europe
In Q1 2024, the pricing dynamics of Amlodipine Besylate in the Europe region underwent fluctuations influenced by various factors. At the beginning of the quarter, prices experienced a slight decline, reflecting subdued consumer sentiments and concerns about the economy. This decline in demand from both the pharmaceutical and healthcare sectors contributed to the decrease in prices for Amlodipine Besylate. However, prices surged in the middle of the quarter due to several factors, including rising consumer demand, logistical challenges, and limited inventories within the domestic market. Disruptions in shipping and logistics, typical during the Spring festival in China, led to delays and increased transportation expenses. These additional costs were passed on to buyers, contributing to the upward trend of Amlodipine Besylate prices. Nevertheless, prices experienced a significant decline again in March as the market grappled with persistently poor performance in new industrial orders. This was characterized by inadequate domestic demand juxtaposed against a relatively high backlog, further contributing to the downward trajectory of prices for Amlodipine Besylate in the Europe region. However, compared to the last quarter of 2023, there was a slight decrease in prices. Finally, the final quarter's price for Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany was reported as USD 72150/MT.
For the Quarter Ending December 2023
North America
In the fourth quarter of 2023, the pricing of Amlodipine Besylate in the North America region was influenced by several key factors. Firstly, the market experienced a bearish trend due to persistent inflation and historically high interest rates, which led to diminished consumer confidence and a decline in demand.
Among the countries in the region, the United States saw significant changes in Amlodipine Besylate prices. The country faced challenges from inflation and high interest rates, resulting in a decrease in consumer confidence and a weakened demand for the product. However, there was a slight improvement in November, driven by a decrease in inflation and a rebound in consumer spending. There was no significant percentage change in the prices compared to the previous year's fourth quarter. However, there was a slight decrease of -1% in prices from the previous quarter in 2023.
Overall, the Amlodipine Besylate market in the North America region in the fourth quarter of 2023 was influenced by factors such as inflation, interest rates, and consumer confidence. The pricing in the USA experienced fluctuations but ended the quarter at USD 75195/MT.
APAC
The fourth quarter of 2023 for Amlodipine Besylate in the APAC region was characterized by various factors that influenced the market and prices. Firstly, there was an overall stability in the market, with a moderate to high supply of Amlodipine Besylate available. However, demand remained weak, primarily due to reduced orders from both local and international markets. Additionally, the manufacturing sector in China experienced fluctuations, with a rebound in November, driven by strengthening domestic demand, but still facing challenges from weak external demand. China, being a key player in the market, witnessed a decrease in Amlodipine Besylate prices during this quarter. The prices in October saw a decline due to declining demand and ample supply in the domestic market. However, prices increased in November as demand started to pick up from end-user industries, leading to replenishment of inventories. By December, prices dropped again due to lower demand and trade activity remaining subdued. The price of Amlodipine Besylate (USP, FDA) FOB Shanghai in China for the current quarter is USD 73850/MT. Overall, the market for Amlodipine Besylate in the APAC region in Q4 2023 was influenced by weak demand, ample supply, and fluctuations in the manufacturing sector, particularly in China.
Europe
The pricing of Amlodipine Besylate in Europe during the fourth quarter of 2023 was influenced by several key factors. Firstly, the market experienced a decline in demand from end-user sectors, particularly in Germany, the country with the most significant price changes. This weakening demand can be attributed to persistent inflationary pressures caused by rising food and energy costs, which have strained consumers' purchasing power. Additionally, the implementation of higher interest rates by the European Central Bank (ECB) further curtailed market demand and kept prices on the lower side. Furthermore, the ample availability of supply in the market contributed to the decline in prices. Market providers lowered prices to clear out their inventories, as warehouses had sufficient stock. In terms of price trends, there was a -2% decrease in prices compared to the previous quarter, indicating a downward movement. The price comparison between the first and second half of the quarter showed no significant change. Overall, the pricing of Amlodipine Besylate in Europe during the fourth quarter of 2023 was influenced by weakened demand, high inflation, the implementation of higher interest rates, and ample supply in the market. The latest price for Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany for this quarter is USD 74677/MT.
For the Quarter Ending September 2023
North America
Amlodipine Besylate prices declined by 19.44% in September 2023 when compared to July levels. Business activity in the United States declined in the third quarter due to lower demand from both domestic and international markets. In the United States, inflation climbed to 3.7% in August for the first time since June 2022, as a strong rise in energy prices pushed prices higher near the end of the summer, impacting even more on consumer confidence. Inflationary pressures suggest that the US economy is moving away from the Federal Reserve's 2% target rate, pushing officials to contemplate hiking interest rates later this year. The Federal Reserve hiked its key policy interest rate by 0.25 percent in July, the eleventh time in 17 months, to combat persistent inflation in the US economy, which has resulted in lower market demand. In September, inflation remained high, owing mostly to higher gas and rental prices, which put further strain on consumers. New orders fell for the sixth consecutive month, albeit at a slower pace, resulting in a drop in Amlodipine besylate pricing. Prices concluded at USD 76290/MT CFR Los Angeles at the end of Q3.
Asia Pacific
Amlodipine Besylate prices in China declined 19.05 percent in September compared to July levels. The Chinese economy was confronted with new impediments and challenges, which slowed economic development. According to the National Bureau of Statistics (NBS), the official manufacturing PMI (Purchasing Managers' Index) was 49.3 in July. This value, however, remained below 50, indicating contraction rather than expansion. Business and production activity has slowed down because of lower international orders and sales. Inflation and rising interest rates in the United States, Europe, and key export markets continue to weigh on Chinese demand, with the new export order sub-index falling in August for the sixth month in a row. China's manufacturing purchasing managers' index (PMI) was 50.2 in September, returning to the expansion zone. This data reveals that manufacturing market demand has gradually improved, and business operations have increased at a faster rate. However, Chinese exporters have continued to face political difficulties and a concerted international push to reduce reliance on China, resulting in a drop in demand from overseas markets. Prices stabilized at USD 75000/MT USP FOB Shanghai at the end of Q3.
Europe
Since the beginning of the third quarter, the price of Amlodipine Besylate in Germany has reduced by 18.95% in September. In Germany, the purchasing managers' index (PMI) dipped to 41 in July, showing a sustained fall in new orders from both domestic and foreign markets despite adequate stocks among market players. Furthermore, as a result of repeated rate rises, rising inflation, the oil crisis, and geopolitical factors, consumer confidence remained low in August. The continuation of high inflation, fueled by high energy and oil prices, harmed consumer spending power and aided the decline in Amlodipine Besylate prices. The industrial sector in Germany, which accounts for roughly one-fifth of the country's economy, remained in a slump in September owing to sluggish demand and rapidly declining output, which also resulted in a drop in Amlodipine Besylate prices. Consumer uncertainty, significant stock reduction measures, and a drop in business activity all contributed to weaker demand. With the termination of Q3, the prices settled at USD 75820/MT CFR Hamburg.
For the Quarter Ending June 2023
North America
Amlodipine besylate prices dropped by 3.41% in June 2023 from levels seen in April. The US Manufacturing PMI (Purchasing Managers Index) fell to 46.3 in June, from 48.4 in May and 47.1 in April, suggesting the decline in end consumer purchases. Due to lower demand in the market, traders and suppliers have reduced the price of Amlodipine Besylate to liquidate existing inventory in order to maintain their profitability. The consumer price index (CPI), an indicator of inflation, inclined just 0.2% in June from 0.1% in May, indicating a slower pace of inflation in more than two years as the Federal Reserve raised interest rates sharply to bring inflation down. This lowered the end-user demand in the market, putting downward pressure on prices. In addition, the US dollar strengthened against the Chinese yuan in the second quarter, making imports cheaper, leading to an increased supply of APIs (active pharmaceutical ingredients), including amlodipine besylate in the US market, supporting the downward trend of prices.
Asia Pacific
The prices of Amlodipine besylate decreased by 3.65 percent in June 2023 compared to the levels observed in April. The factors responsible for this trend include increased supply, weaker demand, and weaker trade activity. As per the National Bureau of Statistics (NBS), China's manufacturing PMI (Purchasing Managers' Index) settled at 49 in June, compared to 48.8 in May and 49.2 in April, demonstrating the contraction in the manufacturing sector. The production activity declined in the second quarter because of weakened demand from end-consumers with declining purchasing activity and a fall in new orders indicating China's post-pandemic slowed down. The supply chain continued to disrupt as a result of the war in Ukraine, which affected the exporting activity that increased the supply in the Chinese domestic market, putting downward pressure on prices. Apart from this, China's consumer price index (CPI), a key indicator of inflation, remained flat year-on-year in June compared to a 0.2% annual increase in May, according to the National Bureau of Statistics, that further explains lower Amlodipine besylate prices.
Europe
In Germany, a 4.25% downward trend in the Amlodipine Besylate price was observed in June since the beginning of the second quarter. Increased supply, decreased downstream demand, and currency fluctuation supported this downward trend. The euro strengthened against the US dollar, increasing the supply of amlodipine besylate in the German market by making imports cheaper. Manufacturers, suppliers, and merchants are focusing on clearing inventory, which has caused prices to continue to fall. Additionally, the manufacturing PMI (Purchasing Managers Index) fell to 41 in June, from 43.2 in May and 44.5 in April, indicating a contraction in the manufacturing sector with purchasing activity falling. Increased supply of generic version of Amlodipine besylate due to ease of regulation also contributed to decreased prices. The German economy is being hit by high inflation and interest rate hikes by the European Central Bank, pushing up food and energy prices. This has increased the cost of living, reduced the purchasing power of consumers, and put downward pressure on prices.
For the Quarter Ending March 2023
North America
In the first quarter of 2023, Amlodipine Besylate showed stable appreciation in the price trajectory. Prices rose at the start of Q1 2023 and stayed up through the end of February thanks to merchant supplies to satisfy demand and ongoing purchases from the pharmaceutical end-user business. The settlement price of Amlodipine Besylate API was reported at USD 51520/MT CFR New York, with an average quarterly inclination of 0.70%. Additionally, the market position was favorably impacted by improved trade flow and simpler logistic charges than the previous quarter. On the other hand, prices stabilize from the beginning of February till the termination of March due to sufficient stocks, low-end-user sector offtakes, and a decrease in freight costs.
Asia
Amlodipine Besylate prices witnessed a positive trajectory in the APAC region in the first quarter of 2023. The prices surged considerably at the commencement of Q1 2023, with the demand from both the domestic and international markets for the replenishment of their inventories with fresh stock. Also, increased production activities kept the market situation strong. With the commencement of February 2023, After the Lunar New Year break, the Chinese pharmaceutical markets technically returned on a positive note with consistent orders from both the domestic and the international market. As the market was reopened, factory and port operations resumed. At the termination of Q1 2023, the settlement price of Amlodipine Besylate API accessed at USD 34100/MT FOB Shanghai with an average quarterly inclination of 1.24%.
Europe
Amlodipine Besylate's price trajectory showed consistent appreciation in the first quarter of 2023. Due to merchant supply to meet demand and continued purchases from the pharmaceutical end-user sector, prices increased at the beginning of Q1 2023 and remained up until the end of February. Amlodipine Besylate API's settlement price was reported to be USD 54560/MT CFR Hamburg, with a quarterly average inclination of 1.05%. The market position also benefited from an increase in trade flow and simpler logistic costs compared to the previous quarter. On the other hand, prices stabilize from the start of February to the end of March as a result of adequate stocks, offtakes from the low-end consumer sector, and a decline in freight costs.
For the Quarter Ending December 2022
North America
The North American Amlodipine Besylate market commenced in Q4 of 2022 on a declining note, with CFR New York prices settling at USD 51600/MT in October. The interrupting imports from China during the Golden week vacations in the first week of October resulted in low inventories among domestic retailers. Additionally, demand from the downstream pharmaceutical sector in the United States remained sluggish. However, these prices continued to drop in November and fell even further to USD 50460/MT in December in the US domestic market. The US supply chain gradually became better in H2 of 2022 as the country finally started to recover, and the port on the east coast significantly reduced ship backlogs. The US supply chains were adaptable because of the reduced shipping demand brought on by slower consumer spending and a decline in manufacturing activity in December. All these factors had a prominent effect on the downward price trend of Amlodipine Besylate in the US domestic market. York
Asia- Pacific
The price trend for Amlodipine Besylate in the Asia Pacific region showed a downward trajectory in the Q4 of 2022. The Golden week closure of industrial facilities in China from October 1 and 7 resulted in a slow rate of contraction in the manufacturing sector this month. During the first half, merchants received orders from domestic and international buyers for urgent use only, and Amlodipine Besylate prices came to USD 33900/MT FOB Shanghai in October. However, after returning from the Golden week holiday, the industries resumed production, and the domestic manufacturers and suppliers met the total demand during the quarter with an acceptable supply of inventories on hand. Following the government’s decision to relax its zero-covid regulation in response to widespread protest and ubiquitous unrest in the country, which put the country once again in choppy waters, cases of Covid-19 started to appear in the key manufacturing hubs in China, which shocked the market yet again. Therefore, the chances of Amlodipine Besylate prices catching up to the modest increase in H2 of Q4 were decreased to USD 32870/MT in December.
Europe
German domestic market displayed weakening sentiments in the Q4 of 2022 as prices dropped from USD 54200/MT to USD 52870/MT from October to December. The primary factor for the ultimate decrease in price was the adequate availability of the product in the German market coupled with bearish demand from downstream pharmaceutical and healthcare industries. The price plunged was also initiated by dwindling offtakes from the domestic market, causing muted purchasing activity. Also, imports from Asia-Pacific countries had become normal as prices their drop due to Covid 19 issues. Moreover, the situation in Russia and the state of war in Ukraine all continued to have a detrimental effect on output. In the second half, only fewer traders were active in the market as they already had sufficient inventories and mainly waiting for a fresh supply. The pessimistic market sentiment provoked traders to get rid of their ample stock levels at a lower price.
For the Quarter Ending September 2022
North America
In the North American region, the Amlodipine Besylate price trend observed an increasing trajectory in the third quarter of 2022 owing to enhanced demand from the downstream segment and limited supply among domestic traders. However, Amlodipine Besylate inventories were low in the domestic market due to lesser imports from the international market on account of lockdown restrictions and production on hold amidst maintenance work. Moreover, the buying activities were elevated due to rising offtakes from end-user pharmaceutical and healthcare sectors. Therefore, the CFR New York prices for Amlodipine Besylate in the United States displayed a 13.1% quarterly increment, with prices surging from USD 48200/MT to USD 52300/MT.
Asia- Pacific
In the Asia Pacific, Amlodipine Besylate witnessed favorable market sentiments during the third quarter of 2022. However, FOB Shanghai prices increased from USD 34070/MT to USD 34770/MT from July to September 2022. The robust demand from several end-user pharmaceutical and healthcare industries has impacted the Amlodipine Besylate prices in the Chinese market. Various manufacturing factories underwent maintenance after the shutdown when the markets reopened in the closing week of July, which impacted the product supply in domestic and foreign suppliers throughout the H2 of the quarter. The market dynamics in China over the final weeks of Q3 were also badly influenced by extreme weather and economic issues.
Europe
In Europe, the Amlodipine Besylate prices resembled the similar market dynamics of North America and the Asia Pacific region. However, in Germany, the third quarter of 2022 saw an incline upto 12.1% in the price of Amlodipine Besylate, with CFR Hamburg values settled at USD 51200/MT in July and then rising even further to USD 56300/MT in September. The reason behind the price incline was hindered supplies and consistent demand from end-user industries. Also, water levels on the Rhine in Germany continue to fall in hot weather, resulting in higher shipping costs and disruption in trade activities, influencing the prices of Amlodipine Besylate to upsurge. Furthermore, rising import costs have forced domestic firms to alter their product lines to enhance profit margins.
For the Quarter Ending June 2022
North America
The North American region dominates the Amlodipine Besylate API market with rising adoption of strategies by manufacturers in their unit. In the second quarter of 2022, Amlodipine Besylate API market sentiments in North America remained positive, with prices surging by 7.6% throughout the quarter. Due to the low production rate, there were insufficient inventories in the regional market to meet the firm demand pattern of Amlodipine Besylate in the regional market. Following the high cost of feedstock Amlodipine and Benzene sulfonate, Amlodipine Besylate prices increased in Q2 2022. In contrast, the prices stabilized in the second half of Q2 due to adequate supplies, and regular trading activities contributed to the stable prices in the month of June. The CFR prices for Amlodipine Besylate API were assessed at USD 46000/MT at the end of the quarter in the United States.
Asia- Pacific
In the second quarter of 2022, the Asia Pacific market witnessed seesaw sentiments for Amlodipine Besylate API due to fluctuating demand from downstream pharmaceutical industries. The prices of Amlodipine Besylate API in the Indian market surged by 9.4% till May but started to scale down slightly in June. Supply chain disruption and port congestion issues due to the lockdown in China for two months affected the price trend of Amlodipine Besylate. However, demand from downstream pharmaceutical industries has been strong owing to limited inventories, encouraging the buyer's sentiment in the domestic market. By the end of the quarter, improvement in import frequencies from China led to adequate stock in the market, causing the value of Amlodipine Besylate to be slightly lower. Thus, by the end of June, Amlodipine Besylate API prices were assessed at USD 31145/MT in China.
Europe
During Q2 2022, the Europe Amlodipine Besylate API market also improved overall. In early Q2, Amlodipine Besylate prices rose in the European region. The uphill curve owed to the worsening economic crisis against the backdrop of the Russia-Ukrainian conflict. High prices of raw materials, and supply shortages, had a considerable effect on production rates and operational costs in the international market, affecting the price trend of Amlodipine Besylate. In addition, with the lockdown in China, importing activities were reduced, which lessened the availability of the Amlodipine Besylate API in the European market. As a result, enhanced demand from downstream pharmaceutical industries could not meet in the domestic market. The prices of Amlodipine Besylate API in Germany were settled at USD 50000/MT by the end of June.
